Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2985908 | 0.84 | OPRM1 (0.52) | SIGMAR1HPGDOPRM1OPRL1SMN1; SMN2 | |
| SCHEMBL2984696 | 0.83 | HPGD (0.46) | SIGMAR1HPGDOPRM1OPRL1SMN1; SMN2 | |
| SCHEMBL2985326 | 0.82 | HPGD (0.50) | HPGDSMN1; SMN2ALDH1A1HTTNPC1 | |
| SCHEMBL2989227 | 0.81 | BCHE (0.41) | SIGMAR1HPGDOPRM1OPRL1SMN1; SMN2 | |
| SCHEMBL2976760 | 0.81 | SIGMAR1 (0.44) | SIGMAR1OPRM1OPRL1ALDH1A1NPC1 | |
| SCHEMBL4050176 | 0.80 | CCR2 (0.43) | SIGMAR1OPRM1OPRL1 | |
| SCHEMBL4055346 | 0.80 | ACKR3 (0.48) | SIGMAR1HPGDOPRM1OPRL1ALDH1A1 | |
| SCHEMBL2978646 | 0.80 | ALDH1A1 (0.48) | HPGDALDH1A1L3MBTL1HTT | |
| SCHEMBL2981361 | 0.79 | ATF4 (0.57) | HPGDSMN1; SMN2ALDH1A1HTTRAB9A | |
| SCHEMBL16143668 | 0.78 | SIGMAR1 (0.37) | SIGMAR1HPGDOPRM1OPRL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786328-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2010-08-31 | — | — | US | claimed |
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-12-06 | — | — | US | claimed |
| US-7786328-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2010-08-31 | — | — | US | disclosed |
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | DPYD, PKD1, AOC1 | SIGMAR1 1253/4885HPGD 162/4885OPRM1 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.